Zhongxiu Hu

Ms. Zhongxiu Hu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
QXQing Xiong
Qing Xiong
XHXinzi He
Xinzi He
Elisa ScalcoElisa Scalco
Elisa Scalco
SPSiria Pasini
Siria Pasini
CZChenglin Zhu
Chenglin Zhu
Martin R PrinceMartin R Prince
Martin R Prince
Key Points: TraceOrg is a web-based tool that automatically labels kidney, liver, and cysts, reporting volumes and Mayo Imaging Classification. External validation showed high performance and good generalizability on Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Polycystic Kidney Disease-Research Resource Consortium, and other external datasets. Training on multiple pulse sequences enables TraceOrg to process images from a wide variety of protocols. Background: Kidney, liver, and cyst volumes are important for diagnosis, classification, and management of autosomal dominant polycystic kidney disease (ADPKD) but challenging to measure accurately and reproducibly. Here, we develop a web-based deep learning platform to automatically and robustly measure kidneys, liver, and cyst volumes in ADPKD. Methods: Magnetic resonance imaging (MRI) and computed tomography scans from patients with ADPKD ( n =611) and participants without ADPKD ( n =109) were used to train a 3D hybrid model combining U-Net and transformer elements for segmenting kidneys, liver, and cysts. The model is implemented as a web-based calculator at www.traceorg.com, providing segmentation labels, volumes, and Mayo Clinic Image Classification. Automatic browser anonymization of digital imaging and communications in medicine images ensures privacy. Internal validation was conducted on 70 MRIs for kidney and liver segmentations and 46 MRIs for cyst segmentations, and performance was compared with five open access segmentation models (TotalSegmentator, MRAnnotator, Kim, Woznicki, and Gregory–Kline). External validation was performed on one single-center dataset ( n =58), one multicenter dataset ( n =73), Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease 2 (CRISP, n =30), and Polycystic Kidney Disease-Research Resource Consortium (PKD-RRC, n =115) MRIs with T2-weighted and T1-weighted images. Results: After training on 720 participants (mean age=48±15, eGFR=74±32 ml/min per 1.73 m 2 and height-adjusted total kidney volume=826±772 ml/m), TraceOrg internal validation performance achieved high mean Dice scores of 0.97 (kidneys), 0.97 (liver), 0.93 (kidney cysts), and 0.82 (liver cysts) outperforming existing models for ADPKD. External validation showed strong performance with Dice scores of 0.92–0.94 (kidney), 0.87–0.96 (liver), 0.85 (kidney cysts), and 0.76–0.90 (liver cysts) for the single-center dataset and 0.95 (kidney) and 0.81 (kidney cysts) for the multicenter dataset. Compared with CRISP volumes measured by stereology, the mean absolute percent difference was 5.3% (kidneys, n =30), 11% (kidney cysts, n =30), and 5.5% (liver, n =22). Compared with PKD-RRC ( n =115), the mean absolute percent difference in total kidney volume was 4.9%. Conclusions: TraceOrg, a publicly available web-based tool, automatically measured kidney, liver, and cyst volumes from abdominal MRI in ADPKD with high accuracy compared with manual segmentations. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2026_02_03_ASN0000000904.mp3

Verified
Journal Article
Open access
PDF file
Vahid BazojooVahid Bazojoo
Vahid Bazojoo
VDVahid Davoudi
Vahid Davoudi
JBJon Blumenfeld
Jon Blumenfeld
CZChenglin Zhu
Chenglin Zhu
LMLine Malha
Line Malha
Martin R PrinceMartin R Prince
Martin R Prince
Background/Objectives: Polycystic liver disease (PLD) is the most common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). PLD is more prevalent in women, and women have larger liver cysts, possibly due to estrogen-related mechanisms. Maternal estrogen levels normally increase during pregnancy. Thus, we investigated the pregnancy-associated increase in liver volume, liver cyst volume, total kidney volume (TKV), and kidney cyst growth rates in ADPKD patients. Methods: Kidney, liver, and cyst volumes were measured in 16 ADPKD patients by magnetic resonance imaging (MRI) at multiple timepoints before and after pregnancy. The log-transformed TKV, liver volume, and cyst volume growth rates during a period with pregnancy were compared to a period without pregnancy. Results: In ADPKD patients, a higher annualized liver cyst growth rate was observed during a period with pregnancy compared to a period without pregnancy (34 ± 16%/yr vs. 23 ± 17%/yr; p-value = 0.005). Liver volume growth was also higher during a period with pregnancy, 6 [2, 7]%/yr vs. 0.3 [−0.4, 2]%/yr (p-value = 0.04). In addition, the mean kidney cyst growth rate was higher (12 ± 11%/yr vs. 4 ± 9%/yr; p-value = 0.05), and there was a trend toward a pregnancy-associated increase in the TKV growth rate (6 [4, 8]%/yr vs. 3 [0.8, 5]%/yr, (p-value = 0.14) during a period with pregnancy. Conclusions: In patients with ADPKD, the liver volume and cyst volume growth rates increased during pregnancy. This supports the hypothesis that the estrogen-mediated stimulation of liver cyst growth may contribute to the severe polycystic liver disease that is more prevalent in women than men with ADPKD. Further studies with larger populations are needed to explore the mechanisms and long-term implications of these findings.

21 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HDHreedi Dev
Hreedi Dev
ZHZhongxiu Hu
Zhongxiu Hu
JBJon Blumenfeld
Jon Blumenfeld
Arman SharbatdaranArman Sharbatdaran
Arman Sharbatdaran
YKYelynn Kim
Yelynn Kim
Martin R PrinceMartin R Prince
Martin R Prince
Background/Objectives: Although tolvaptan efficacy in ADPKD has been demonstrated in randomized clinical trials, there is no definitive method for assessing its efficacy in the individual patient in the clinical setting. In this exploratory feasibility study, we report a method to quantify the change in total kidney volume (TKV) growth rate to retrospectively evaluate tolvaptan efficacy for individual patients. Treatment-related changes in estimated glomerular filtration rate (eGFR) are also assessed. Methods: MRI scans covering at least 1 year prior to and during treatment with tolvaptan were performed, with deep learning facilitated kidney segmentation and fitting multiple imaging timepoints to exponential growth in 32 ADPKD patients. Clustering analysis differentiated tolvaptan treatment “responders” and “non-responders” based upon the magnitude of change in TKV growth rate. Differences in rate of eGFR decline, urine osmolality, and other parameters were compared between responders and non-responders. Results: Eighteen (56%) tolvaptan responders (mean age 42 ± 8 years) were identified by k-means clustering, with an absolute reduction in annual TKV growth rate of >2% (mean = −5.1% ± 2.5% per year). Thirteen (44%) non-responders were identified, with <1% absolute reduction in annual TKV growth rate (mean = +2.4% ± 2.7% per year) during tolvaptan treatment. Compared to non-responders, tolvaptan responders had significantly higher mean TKV growth rates prior to tolvaptan treatment (7.1% ± 3.6% per year vs. 3.7% ± 2.4% per year; p = 0.003) and higher median pretreatment spot urine osmolality (Uosm, 393 mOsm/kg vs. 194 mOsm/kg, p = 0.03), confirmed by multivariate analysis. Mean annual rate of eGFR decline was less in responders than in non-responders (−0.25 ± 0.04, CI: [−0.27, −0.23] mL/min/1.73 m2 per year vs. −0.40 ± 0.06, CI: [−0.43, −0.37] mL/min/1.73 m2 per year, p = 0.036). Conclusions: In this feasibility study designed to assess predictors of tolvaptan treatment efficacy in individual patients with ADPKD, we found that high pretreatment levels of annual TKV growth rate and higher pretreatment spot urine osmolality were associated with a responder phenotype.

20 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
CZChenglin Zhu
Chenglin Zhu
XHXinzi He
Xinzi He
JBJon Blumenfeld
Jon Blumenfeld
ZHZhongxiu Hu
Zhongxiu Hu
HDHreedi Dev
Hreedi Dev
Martin R PrinceMartin R Prince
Martin R Prince
Abdominal imaging of autosomal dominant polycystic kidney disease (ADPKD) has historically focused on detecting complications such as cyst rupture, cyst infection, obstructing renal calculi, and pyelonephritis; discriminating complex cysts from renal cell carcinoma; and identifying sources of abdominal pain. Many imaging features of ADPKD are incompletely evaluated or not deemed to be clinically significant, and because of this, treatment options are limited. However, total kidney volume (TKV) measurement has become important for assessing the risk of disease progression (i.e., Mayo Imaging Classification) and predicting tolvaptan treatment’s efficacy. Deep learning for segmenting the kidneys has improved these measurements’ speed, accuracy, and reproducibility. Deep learning models can also segment other organs and tissues, extracting additional biomarkers to characterize the extent to which extrarenal manifestations complicate ADPKD. In this concept paper, we demonstrate how deep learning may be applied to measure the TKV and how it can be extended to measure additional features of this disease.

16 July 2024 in Tomography
Verified
Journal Article
Open access
PDF file
SWSophie J. Wang
Sophie J. Wang
ZHZhongxiu Hu
Zhongxiu Hu
CLCollin Li
Collin Li
XHXinzi He
Xinzi He
CZChenglin Zhu
Chenglin Zhu
Martin R PrinceMartin R Prince
Martin R Prince
Background: Pancreatic cysts in autosomal dominant polycystic kidney disease (ADPKD) correlate with PKD2 mutations, which have a different phenotype than PKD1 mutations. However, pancreatic cysts are commonly overlooked by radiologists. Here, we automate the detection of pancreatic cysts on abdominal MRI in ADPKD. Methods: Eight nnU-Net-based segmentation models with 2D or 3D configuration and various loss functions were trained on positive-only or positive-and-negative datasets, comprising axial and coronal T2-weighted MR images from 254 scans on 146 ADPKD patients with pancreatic cysts labeled independently by two radiologists. Model performance was evaluated on test subjects unseen in training, comprising 40 internal, 40 external, and 23 test–retest reproducibility ADPKD patients. Results: Two radiologists agreed on 52% of cysts labeled on training data, and 33%/25% on internal/external test datasets. The 2D model with a loss of combined dice similarity coefficient and cross-entropy trained with the dataset with both positive and negative cases produced an optimal dice score of 0.7 ± 0.5/0.8 ± 0.4 at the voxel level on internal/external validation and was thus used as the best-performing model. In the test–retest, the optimal model showed superior reproducibility (83% agreement between scan A and B) in segmenting pancreatic cysts compared to six expert observers (77% agreement). In the internal/external validation, the optimal model showed high specificity of 94%/100% but limited sensitivity of 20%/24%. Conclusions: Labeling pancreatic cysts on T2 images of the abdomen in patients with ADPKD is challenging, deep learning can help the automated detection of pancreatic cysts, and further image quality improvement is warranted.

12 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
Arman SharbatdaranArman Sharbatdaran
Arman Sharbatdaran
TCTéa Cohen
Téa Cohen
HDHreedi Dev
Hreedi Dev
USUsama Sattar
Usama Sattar
VBVahid Bazojoo
Vahid Bazojoo
Martin R PrinceMartin R Prince
Martin R Prince
Background/Objectives: Accurate and reproducible spleen volume measurements are essential for assessing treatment response and disease progression in myelofibrosis. This study evaluates techniques for measuring spleen volume on abdominal MRI. Methods: In 20 patients with bone marrow biopsy-proven myelofibrosis, 5 observers independently measured spleen volume on 3 abdominal MRI pulse sequences, 3D-spoiled gradient echo T1, axial single-shot fast spin echo (SSFSE) T2, and coronal SSFSE T2, using ellipsoidal approximation, manual contouring, and 3D nnU-Net model-assisted contouring comparing coefficients of variation. Changes in spleen volume were compared to all information to assess which measurement technique tracked disease progression with the greatest accuracy. Results: The coefficient of variation in spleen volume measurements averaging over 3 sequences was significantly lower for model-assisted contouring, 1.6% and manual contouring, 3.5%, compared to ellipsoidal estimation from 3 dimensions measured on axial and coronal T2 images, 15, p < 0.001. In 4 subjects with divergent treatment response predictions, model-assisted contouring was consistent with all information while ellipsoidal estimation was not. Manual contouring tracked similarly to model-assisted contouring but required more operator time. Conclusions: Model-assisted segmentations provide efficient and more reproducible spleen volume measurements compared to estimates of spleen volume from ellipsoidal approximations and improve objective determinations of clinical trial enrollment eligibility based upon spleen volume as well as assessments of treatment response.